Medical Oncology

Papers
(The TQCC of Medical Oncology is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Oncotype DX testing does not affect clinical practice in stage IIa colon cancer44
The genomic architecture of metastasis in breast cancer: focus on mechanistic aspects, signalling pathways and therapeutic strategies44
The immunomodulatory effects of Candida albicans isolated from the normal gastrointestinal microbiome of the elderly on colorectal cancer33
PSMA: a game changer in the diagnosis and treatment of advanced prostate cancer27
The combined therapy of miR-383-5p restoration and paclitaxel for treating MDA-MB-231 breast cancer26
The role of inflammatory indices in the outcome of COVID-19 cancer patients25
COVID-19 pandemic: a new cause of unplanned interruption of radiotherapy in breast cancer patients25
How to ensure uninterrupted treatment of radiotherapy patients during delta variants of SARS-CoV-2 virus epidemic: the latest experience from Xi’an, China24
Regulatory mechanisms of heme regulatory protein BACH1: a potential therapeutic target for cancer20
Triple-arm androgen blockade for advanced prostate cancer: a review20
Can the host immune response against SARS-CoV2 also cause an anticancer effect?19
Detection of mutations in CML patients resistant to tyrosine kinase inhibitor: imatinib mesylate therapy19
Identification of the role of mono-ADP-ribosylation in colorectal cancer by integrated transcriptome analysis19
DNMT1 and miRNAs: possible epigenetics footprints in electromagnetic fields utilization in oncology18
The inhibition of Panc1 cancer cells invasion by hAMSCs secretome through suppression of tyrosine phosphorylation of SGK223 (at Y411 site), c-Src (at Y416, Y530 sites), AKT activity, and JAK1/Stat3 si17
The “collateral damage” of the war on COVID-19: impact of the pandemic on the care of epithelial ovarian cancer17
Notch signaling in oral pre-cancer and oral cancer16
Innovation in cancer therapeutics and regulatory perspectives15
Enhancement of Apo2L/TRAIL signaling pathway receptors by the activation of Klotho gene with CRISPR/Cas9 in Caco-2 colon cancer cells15
ARA-linker-TGFαL3: a novel chimera protein to target breast cancer cells15
sABLATE: a simplified ABLATE score for prediction of complications and outcome in percutaneous thermal ablation of renal lesions14
Levofloxacin might be safe to use for OSCC patients13
A linkage between effectual genes in progression of CRC through canonical and non-canonical TGF-β signaling pathways13
Upfront metastasis-directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistance13
AFP peptide (AFPep) as a potential growth factor for prostate cancer13
Mefenamic acid as a promising therapeutic medicine against colon cancer in tumor-bearing mice13
Overcoming resistance to targeted therapy using MET inhibitors in solid cancers: evidence from preclinical and clinical studies13
Impact of intravesical instillation of a novel biological response modifier (P-MAPA) on progress of non-muscle invasive bladder cancer treatment in a rat model13
Systematic identification of the cancer pathways and molecules related with breast cancer immunogenicity13
PARP1-modulated chromatin remodeling is a new target for cancer treatment13
Combined evaluation of proliferation and apoptosis to calculate IC50 of VPA-induced PANC-1 cells and assessing its effect on the Wnt signaling pathway13
Computational study on novel natural inhibitors targeting BCL213
Hypofractionated breast irradiation: a multidisciplinary review of the Senonetwork study group13
Interferon regulatory factor-1 regulates cisplatin-induced apoptosis and autophagy in A549 lung cancer cells12
The role of BAFF and G-CSF for rituximab-induced late-onset neutropenia (LON) in lymphomas12
Defining candidate mRNA and protein EV biomarkers to discriminate ccRCC and pRCC from non-malignant renal cells in vitro12
Submicron particle docetaxel intratumoral injection in combination with anti-mCTLA-4 into 4T1-Luc orthotopic implants reduces primary tumor and metastatic pulmonary lesions12
In silico bioinformatics analysis for identification of differentially expressed genes and therapeutic drug molecules in Glucocorticoid-resistant Multiple myeloma11
Knockdown of lncRNA HIF1A-AS2 increases drug sensitivity of SCLC cells in association with autophagy11
Resveratrol triggers anti-proliferative and apoptotic effects in FLT3-ITD-positive acute myeloid leukemia cells via inhibiting ceramide catabolism enzymes11
Direct oral anticoagulants in cancer patients: which help from the specialist hemostasis and thrombosis laboratory?11
AICAR enhances the cytotoxicity of PFKFB3 inhibitor in an AMPK signaling-independent manner in colorectal cancer cells11
ceRNA network development and tumor-infiltrating immune cell analysis in hepatocellular carcinoma11
DNA methylation marker to estimate ovarian cancer cell fraction11
Combination of dasatinib and okadaic acid induces apoptosis and cell cycle arrest by targeting protein phosphatase PP2A in chronic myeloid leukemia cells11
Phase II study of neoadjuvant chemotherapy with S-1 plus oxaliplatin for gastric cancer clinical T4 or N2-311
0.04329514503479